Melphalan

• CHOPIN Pending
  2024-516127-14-01 Phase I (FiH) 1 country Leids Universitair Medisch Centrum (LUMC)
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 Phase III 1 country University Of Cologne
• Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very Hi… Pending
  2024-518912-37-01 Phase II 1 country Fondazione Santobono Pausilipon Onlus
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or V… Recruiting
  2025-521966-91-00 Phase II 2 countries Delcath Systems Inc.
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting
  2024-520356-24-00 Phase II 5 countries Delcath Systems Inc.
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
• Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans… Recruiting
  2023-507879-21-00 Phase II 1 country Technische Universitat Dresden
• Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium Recruiting
  2023-503723-26-00 Phase IV 1 country Universitair Ziekenhuis Gent
• Preparation for bone marrow transplantation through the combined use of chemo and radiotherapy (Reduced intensity: with lower doses or diffe… Recruiting
  2024-514483-11-00 Phase II 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting
  2024-514917-36-00 Phase III 13 countries Institut Gustave Roussy
• TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neurob… Recruiting
  2024-519089-32-02 Phase II 1 country IRCCS Istituto Giannina Gaslini
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 Phase III 6 countries GPOH gGmbH
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• Conservative treatment of patients with retinoblastoma Recruiting
  2024-517275-21-00 Phase II 1 country Institut Curie
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended
  2024-512676-36-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended
  2024-516905-22-00 Phase III 1 country Fundacion PETHEMA
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM… Ended
  2024-512049-17-00 Phase IV 1 country Universita' Degli Studi Di Torino
• An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e… Ended
  2024-516130-35-00 Phase II 1 country Fundacion Pethema
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 Phase III 7 countries Novartis Pharma AG

Showing 1–19 of 19 trials